Author: denaeric@gmail.com

The Cannabinoid Safety and Regulation Act (CSRA), an 84-page piece of proposed federal legislation introduced by Senators Wyden and Merkley in December 2025, represents the most ambitious attempt yet to establish a unified federal safety framework for cannabis and hemp products sold in the United States. If enacted in its proposed form, the CSRA would fundamentally change the compliance landscape for cultivators operating in every state.

What the Bill Proposes

The CSRA’s core provisions include mandatory third-party testing with standardized methodologies across all legal cannabis and hemp products, restrictions on pesticide residues with reference to EPA tolerance levels, limits on heavy metal contaminants, packaging and labeling requirements standardized at the federal level, and prohibitions on chemical byproducts in processed cannabis products.

Critically, the bill proposes federal oversight of the testing laboratories themselves, creating a national accreditation framework that would supersede or complement existing state lab licensing systems. This would directly address the lab fraud and inconsistent testing quality problems that have plagued state-level markets.

What It Would Mean for Cultivators

For cultivators operating in states with robust existing testing requirements, many of the CSRA’s provisions would represent a codification of standards they already meet. For operators in states with minimal requirements, federal legislation would force a rapid upgrade of quality assurance infrastructure.

The proposed mandatory testing regime would also create new documentation and chain-of-custody requirements that add administrative complexity to existing operations. Operators who have already built rigorous internal QA systems would adapt far more easily than those starting from scratch.

The Road Ahead

As of early 2026, the CSRA remained in early legislative stages. But the direction of travel is clear: federal cannabis regulation is coming, and the safety and testing provisions being debated now will shape what compliance looks like for the next decade. Cultivators who are building robust contamination prevention and quality assurance systems today are investing in infrastructure that will pay off regardless of which specific federal framework ultimately emerges.

New York’s Office of Cannabis Management (OCM) published a revised set of laboratory testing limits effective February 2026, updating standards that govern what levels of contaminants are permissible in cannabis products sold in the state’s licensed market. The revisions reflected both evolving scientific understanding of cannabis-specific risks and lessons learned from the lab fraud and compliance failures that had affected the New York market in 2025 and early 2026.

Key Changes to Aspergillus Standards

The February 2026 revision brought greater specificity to how Aspergillus testing is interpreted and reported. Following the discovery that Keystone State Testing New York had issued unreliable Aspergillus results for dozens of product lots, the OCM tightened requirements around how labs must document and validate their Aspergillus testing methodology. Labs are now required to demonstrate proficiency in Aspergillus detection through blind sample testing before being permitted to issue compliance results for New York licensed products.

Broader Contaminant Limit Revisions

The February update also revised action limits for several other contaminant categories. Total yeast and mold action limits were adjusted to better reflect the potency of the state’s Aspergillus-specific requirements. Mycotoxin limits were updated based on emerging research on aflatoxin accumulation in cannabis, and the OCM clarified its approach to residual solvent limits for specific concentrate product types.

Why Compliance Windows Keep Narrowing

New York’s February 2026 revision is part of a consistent pattern visible across every mature regulated cannabis market: testing requirements get more specific, more stringent, and more rigorously enforced over time. What passes today may not pass in 18 months. Cultivators who build their quality assurance programs around current minimums are perpetually at risk of being caught by the next update.

Investing in proactive contamination prevention — rather than relying on the compliance floor staying where it is — is the only sustainable strategy for operations that intend to remain viable as regulatory environments continue to evolve.

California’s cannabis market saw another high-profile mold recall in late 2025 when a voluntary recall was issued for multiple Pure Beauty flower products due to Aspergillus fumigatus contamination. Pure Beauty is a recognized brand in the California market, and the recall underscored that even well-established operators are not immune to the microbial compliance challenges that have plagued the state throughout 2025.

Why Aspergillus fumigatus Is Particularly Dangerous

Of the four Aspergillus species that California mandates testing for, Aspergillus fumigatus is the one that most concerns clinicians. It is the most common cause of invasive aspergillosis in immunocompromised patients and produces thermotolerant spores that can survive conditions hostile to other pathogens. When inhaled into the lungs, A. fumigatus spores can germinate and invade lung tissue in susceptible individuals.

For the vast majority of healthy cannabis consumers, exposure to A. fumigatus is unlikely to cause serious harm. But for the subset of consumers who are immunocompromised — cancer patients, transplant recipients, individuals on long-term corticosteroid therapy — even brief exposure can have severe consequences.

California’s Testing Framework for Aspergillus

California requires testing for four Aspergillus species: A. fumigatus, A. flavus, A. niger, and A. terreus. Any product with a detected result for any of these species fails compliance and cannot be sold in the licensed market. The zero-tolerance approach reflects the state’s assessment of the public health risk posed by Aspergillus contamination in an inhaled product.

Protecting Your Harvest Against Aspergillus

The Pure Beauty recall and others like it across California point to a persistent gap between cultivation practices and compliance outcomes. Post-harvest decontamination technologies that target Aspergillus and other mold species at the microbial level are the most effective way to close that gap. Cultivators who integrate decontamination into their post-harvest workflow are not gambling on a clean test result — they are engineering it.

A Certificate of Analysis (COA) from a licensed cannabis testing lab is supposed to be the gold standard of product safety verification. It is the document that says your flower passed microbial, pesticide, heavy metal, and potency testing and is safe for consumers. But a growing wave of lab fraud cases across the country is raising a disturbing question: how much can you actually trust a passing COA?

The Scale of the Problem

Between 2024 and 2026, at least three major cannabis testing laboratory fraud cases were uncovered in Michigan, New York, and Massachusetts. Each involved deliberate, sustained manipulation of test results — not isolated errors, but intentional falsification of mold, potency, or pathogen findings over months or years. In Michigan, a lab was permanently banned for what regulators described as a sustained, deliberate pattern of fraud. In New York, the Keystone State Testing lab was found to have issued unreliable Aspergillus results for 54 product lots.

How Lab Fraud Happens

Cannabis lab fraud typically falls into several categories. In dilution fraud, samples are diluted to bring contaminant concentrations below detection thresholds. In result substitution, data from a clean sample replaces data from a contaminated one. In instrument manipulation, calibration records or instrument parameters are altered to shift results. Most lab fraud is not detected until a regulatory audit uncovers statistical anomalies or a whistleblower comes forward.

The COA as a False Floor

For cultivators who assume that a passing COA from a licensed lab means their product is genuinely clean, these fraud cases reveal a serious vulnerability. A COA is only as reliable as the integrity of the lab that issued it. Cultivators who rely solely on third-party testing as their quality assurance are placing enormous trust in an institution they often cannot independently verify.

Building Quality Assurance That Does Not Depend on Lab Integrity

The answer is not to abandon lab testing — it remains a critical component of the compliance system. The answer is to not make it the only component. Cultivators who implement proactive post-harvest decontamination know their product is genuinely clean before it reaches any lab. That knowledge is not contingent on the integrity of a third party. It is a measurable, documented quality outcome built into the production process itself.

When it comes to heavy metal testing in cannabis, most regulated states focus on the same four compounds: lead, arsenic, cadmium, and mercury. These four were chosen because they are well-documented human health hazards with established toxicological profiles and EPA reference standards. But emerging research is raising questions about whether the Big Four capture the full scope of heavy metal risk in cannabis products.

Why Cannabis Accumulates Heavy Metals

Cannabis is a known hyperaccumulator, meaning it is unusually effective at drawing contaminants from the soil into its tissues. This property was actually studied as a potential tool for phytoremediation of contaminated land. For cultivators, it means that growing medium composition is a critical quality variable. Any heavy metals present in soil, amended compost, or irrigation water have a pathway into the final product.

What Research Is Showing About Expanded Panels

A review published in Cannabis Science and Technology examined evidence for expanding heavy metal testing panels beyond the standard four compounds. The research looked at chromium, nickel, copper, zinc, barium, and several other metals that appear in cannabis products at measurable levels. While none of these are currently subject to mandatory limits in most U.S. cannabis markets, the authors found sufficient evidence of potential harm to warrant regulatory attention.

For cultivators, this research signals where regulation is likely heading. States that have led on testing requirements in the past — California, New York, Colorado — have a track record of expanding panels as evidence accumulates. Operators who proactively audit their growing media and water sources for expanded heavy metal profiles are building a compliance advantage for the future.

Practical Steps for Cultivators

Request expanded heavy metal analysis from your testing lab, even if the state only requires the Big Four. Audit your growing media and input suppliers for heavy metal content. Maintain records of all soil amendments and irrigation sources. These steps are inexpensive relative to the cost of a compliance failure when expanded panels become mandatory.

The federal definition of hemp has been a moving target since the 2018 Farm Bill established the 0.3% delta-9 THC threshold that separated legal hemp from controlled cannabis. In late 2025, proposed federal legislation sought to redefine that threshold in ways that would create significant new compliance challenges for operators working across state and federal frameworks.

The Proposed Changes

The Cannabinoid Safety and Regulation Act, introduced by Senators Wyden and Merkley in December 2025, proposed establishing comprehensive federal regulations for hemp-derived cannabinoids. Among its provisions were restrictions on THC concentration thresholds that would affect how hemp and cannabis products are classified, along with mandatory third-party testing requirements, standardized packaging, and restrictions on pesticides, heavy metals, and chemical byproducts.

Why the Definition Matters So Much

For cultivators, the difference between hemp and cannabis is not just botanical — it is the difference between operating under state cannabis licensing frameworks and being subject to federal agricultural law. Products that fall on the wrong side of a THC threshold face dramatically different regulatory treatment, including potential federal enforcement action.

The proposed redefinition created anxiety among cultivators who had built their operations around the existing 0.3% threshold and were uncertain whether their genetics, production methods, and market channels would remain viable under a revised federal standard.

The Compliance Implications

Mandatory third-party testing with federal oversight would represent a significant escalation from the current patchwork of state testing requirements. Cultivators who have invested in robust internal quality assurance systems are better positioned to adapt to any federal testing mandate than those who have relied on minimal state compliance requirements.

The broader lesson for cannabis cultivators is that regulatory frameworks are not static. Building compliance infrastructure that exceeds current minimum requirements is the best hedge against a future in which those minimums are raised.

Lab shopping is one of the cannabis industry’s worst-kept secrets. The practice involves submitting product samples to multiple testing laboratories until one returns a passing result, then using that COA to clear the product for retail sale. While not always explicitly illegal, lab shopping undermines the integrity of compliance testing and is increasingly drawing regulatory scrutiny heading into 2026.

How Lab Shopping Works

A cultivator harvests a batch that fails initial testing for mold, yeast, or potency. Rather than destroying the batch or pursuing remediation, the operator submits the same product to a second lab — and if necessary, a third — hoping for a different result. In states without robust lab audit systems, this can succeed, placing non-compliant product into the retail supply chain with a passing COA.

Why Labs Sometimes Produce Different Results

Cannabis testing is not perfectly standardized across labs. Different labs use different sampling methods, different analytical instruments, and different internal quality controls. Legitimate variation in test results exists. But the range of variation from legitimate analytical differences is far narrower than what lab shopping exploits. When a batch fails by a wide margin at Lab A but passes comfortably at Lab B, that is a red flag for regulatory systems designed to detect it.

The 2026 Regulatory Response

States are responding to the lab shopping problem with several tools. Mandatory lab accreditation under ISO 17025 standards is being required in more markets, creating a baseline for analytical competency. Inter-laboratory proficiency testing programs require labs to correctly analyze identical blind samples, identifying outliers. Some states have implemented tracking requirements that capture every lab submission for a given batch, making it impossible to hide sequential submissions.

What Honest Cultivators Should Do

For cultivators who are not engaging in lab shopping, the crackdown is good news. A market where every operator is held to the same standard is a more level playing field. But it also raises the stakes for first-pass compliance. Cultivators who invest in pre-testing decontamination and quality assurance protocols will consistently outperform those who rely on luck at the lab.

An Arizona cannabis establishment made headlines in late 2025 by voluntarily recalling specific products due to possible Aspergillus contamination. While recalls are rarely good news, how this operator handled the situation offers useful lessons for cultivators nationwide.

The Voluntary Recall Advantage

The operator worked directly with the Arizona Department of Health Services to issue a public recall notice, notify retail partners, and begin retrieving affected product from store shelves. A voluntary recall signals that a company has internal quality systems capable of detecting problems and the organizational will to act on them.

Voluntary recalls, while damaging in the short term, often preserve brand equity better than mandatory recalls forced by regulators. Being the one to catch and report the problem is meaningfully better than regulators finding it after product reaches consumers.

Why Aspergillus Is Serious

Aspergillus is a common mold found in soil, air, and organic matter. In healthy individuals, exposure typically causes minor symptoms or none at all. But in immunocompromised individuals, Aspergillus can cause invasive aspergillosis, a life-threatening fungal infection.

Cannabis is often consumed by inhalation directly into the lungs, making Aspergillus spores especially dangerous for at-risk users. This is why state regulators treat Aspergillus contamination as a public health issue warranting mandatory testing and recall authority.

Build a Response Plan Before You Need One

The Arizona case underscores something too few cannabis operators have in place: a documented recall response plan. Operators with pre-established protocols for product notification, retrieval, regulatory communication, and media response manage compliance crises far more effectively than those figuring it out in real time.

Prevention matters most. Post-harvest decontamination that reduces microbial load before compliance testing gives cultivators a meaningful safety margin and makes recalls far less likely from the start.

As cannabis recalls tied to microbial contamination continue to mount across regulated markets, cultivators are increasingly turning to post-harvest decontamination technology to protect their harvests before they reach the testing lab. The options on the market have expanded significantly, and choosing the right system requires understanding what each technology actually does — and where it falls short.

Ozone Treatment

Ozone (O3) treatment exposes harvested flower to controlled concentrations of ozone gas, which oxidizes and destroys microbial cell walls, effectively inactivating bacteria, mold, and spores without heat or liquid solvents. The primary appeal is that ozone leaves no chemical residues. Systems like Willow Industries’ WillowPure have built strong track records in the market.

The main limitation: at high concentrations or extended exposure times, ozone oxidizes terpenes, potentially flattening the aroma and flavor profile of premium flower. Operators must carefully calibrate treatment parameters to balance decontamination efficacy against product quality.

UV-C Light

UV-C light disrupts microbial DNA, preventing reproduction. It’s a surface-level treatment, meaning it works best on exposed areas and may not penetrate dense flower structures where interior mold colonies can survive. UV-C is often used as a supplemental treatment rather than a standalone solution.

X-Ray Irradiation

X-ray irradiation inactivates microbes at the DNA level and operates at room temperature, preserving terpenes, potency, and moisture content. Unlike ozone or UV, X-ray penetrates the full structure of the flower, reaching internal contamination. For 2025 and 2026, X-ray systems are emerging as the leading option for operators who need high efficacy with minimal impact on product quality.

Cold Plasma

Cold plasma is an emerging technology that generates reactive species capable of inactivating microorganisms at low temperatures. Validation data in cannabis applications is still building, and most industry experts position cold plasma as suitable for pilot programs and evaluation rather than primary production systems at scale.

Choosing the Right Fit

The best decontamination technology for your facility depends on your scale, your product types, your target contaminants, and your tolerance for product quality trade-offs. What’s clear across all options: doing nothing is no longer a viable strategy in a market where recalls are becoming routine.

Washington State’s Liquor and Cannabis Board released a detailed research brief on cannabis pesticide testing in January 2026 that should be required reading for every cultivator operating in the state — and a strong signal for operators in other states about where industry standards are heading.

What the Research Found

The brief examined the current landscape of pesticide residue detection in cannabis products, reviewing both the types of pesticides most commonly detected in failed compliance tests and the analytical limitations of testing methods currently used by licensed labs. Among the key findings: certain pesticide compounds that are commonly used in agricultural settings are migrating into cannabis products at levels that exceed state action limits, and some labs lack the analytical sensitivity to reliably detect trace amounts of certain compounds.

This second point is particularly important. If a lab’s detection threshold is higher than the state’s action limit for a given pesticide, it is theoretically possible to have a product that fails compliance but receives a passing test result. Washington’s research brief called for tightening analytical standards at licensed testing facilities to close this gap.

The Pesticide Problem Is Broader Than Most Realize

Many cannabis cultivators assume that because they don’t apply pesticides directly to their plants, they don’t have a pesticide residue problem. This assumption is often incorrect. Pesticides can enter a cultivation facility through contaminated growing media, irrigation water, or even ambient air in areas near conventional agriculture operations. Residual pesticides can also persist in a grow space from previous cultivation cycles.

Steps Cultivators Can Take

Washington’s research underscores the need for cultivators to take pesticide contamination seriously as a systemic risk rather than a compliance technicality. Establishing rigorous incoming material testing protocols, maintaining detailed records of all inputs, and regularly auditing grow environments for potential contamination sources are foundational steps.

As states like Washington continue to tighten pesticide testing requirements and analytical standards, cultivators who build robust quality assurance systems now will be far better positioned than those who wait for a failed test to prompt action.